Breakthrough in HPV MHC-I Tetramer Technology: Deciphering Cervical Cancer Immune Response to Drive Precision Immunotherapy Development

Author: Senior Product Manager of UA Views：510

Human papillomavirus (HPV), classified under the genus Alpha within the Papillomaviridae family, is a non-enveloped, double-stranded circular DNA virus with strict epitheliotropic properties. It primarily targets and infects the squamous epithelial tissues of the skin and mucous membranes.

Recent Advances
Product Information

Recent Advances

HPV MHC Tetramer

HPV (human papillomavirus), a non-enveloped, double-stranded circular DNA virus in the A subgenus of the Papillomaviridae family, has a strict epitheliotropism. Epidemiological studies confirm that 90% of cervical cancers are directly caused by high-risk HPV infections, especially HPV16 and HPV18. Globally, cervical cancer is the fourth most common malignancy in women and the second most common in women aged 15 - 44 years, with approximately 530,000 new cases annually, including about 130,000 in China. Given the strong link between HPV infection and cervical cancer, understanding HPV's oncogenic immune evasion mechanisms and developing targeted immunotherapies is crucial for reducing the disease burden.

HPV Carcinogenic Mechanisms

HPV can invade basal epithelial cells through minor skin trauma. Its infection process is characterized by unique virus - host interactions. HPV DNA can be detected in basal cells without viral capsid protein expression, indicating non - capsid - mediated cytoplasmic transport of the viral genome. The integration of HPV DNA into the host genome is random and not fully understood, but it leads to fundamental changes in viral early gene expression.

Viral genome integration and E2 gene inactivation: HPV DNA integration often disrupts the E2 open reading frame or silences it epigenetically, relieving its transcriptional repression of viral early genes and enabling sustained overexpression of E6/E7 genes. Aberrant functions of E6/E7 oncoproteins: E6 protein: It targets p53 for degradation via the ubiquitin - proteasome pathway, activates hTERT, increases chromosomal instability, inhibits apoptosis, and drives cell immortalization. E7 protein: It binds to and inactivates pRb by phosphorylation, releasing E2F and abnormally activating Cyclin E and Cyclin A while downregulating p16INK4a, leading to cell - cycle dysregulation. Synergistic effects of E5 protein: As a type I transmembrane protein, E5 promotes cell proliferation and immune evasion by activating EGFR signaling and inhibiting MHC - I expression.

Importantly, in p53 - deficient tumor cells, E7 can independently exert anti - apoptotic effects, forming a dual oncogenic drive. Given the continuous high expression of HPV16/18 E6/E7 genes in over 90% of cervical cancers, they are key viral oncogenes and targets for HPV - related cancer immunotherapies.

HPV E6/E7 Therapeutic Vaccine Research

HPV E6 and E7 proteins, the core viral oncoproteins, are abnormally expressed in infected cells. They drive genomic instability and cell - cycle dysregulation, directly causing malignant transformation of cervical epithelial cells. Current research focuses on delivering HPV E6/E7 antigens to antigen - presenting cells (APCs) in various forms. This activates HPV - specific CD8⁺ cytotoxic T lymphocyte (CTL) responses and CD4⁺ helper T - cell responses, creating an immune clearance mechanism targeting viral oncoproteins. The goal is to eliminate virus - infected cells and prevent tumor development by specifically recognizing and killing E6/E7 - positive cells.

Based on delivery systems, HPV therapeutic vaccines can be DNA, subunit, live - vector, or dendritic cell (DC) vaccines. Several E6/E7 - targeted vaccines have entered clinical trials and shown promise in inducing HPV - specific T - cell responses, including CD8⁺ T - cell proliferation, increased IFN - γ secretion, enhanced cytotoxic activity, and higher E6/E7 - specific antibody titers. Notably, some vaccines have elicited immune responses in patients with advanced cervical cancer, providing valuable clinical evidence for HPV - related cancer immunotherapy.

HPV MHC - I Tetramer Technology for Cervical Cancer Immunotherapy Research

CD8⁺ T cells, via TCR, recognize MHC - antigen peptide complexes to eliminate virus - infected and tumor cells. Altman et al. first developed MHC - antigen peptide tetramer technology in 1996, enabling single - cell - level detection and analysis of antigen - specific T cells by flow cytometry. This technology allows simultaneous T cell quantification, phenotyping, and functional assessment and is now a core tool for tumor immunomonitoring.

In HPV - related cancer research, MHC - I tetramer technology efficiently analyzes HPV E6/E7 - specific T - cell responses. It offers key technical support for HPV - targeted vaccine development, TCR - T cell therapy, and immunotherapy - efficacy monitoring.

Related Products:

Disease Category	Product Name	Antigen	Sequence	MHC	Position	Product Number
EBV	HLA-A*0201/YLELLVWRL-PE Labelled Tetramer	EBV.LMP1	YLELLVWRL	HLA-A*0201	125-133	UA089001
EBV	HLA-A*0201/YLQQNWTL-PE Labelled Tetramer	EBV.LMP1	YLQQNWTL	HLA-A*0201	159-167	UA089003
EBV	H-2Db(b)/RAHY-NIVTF-PE Labelled Tetramer	HPV16.E7	RAHYNIVTF	H-2Db	49-57	UA089002
HPV	H-2K(b)/EVYDFA-FRQL-PE Labelled Tetramer	HPV16.E6	EVYDFARDL	H-2Kb	48-57	UA089004
HPV	HLA-A*0201/KLP-DLCTL-PE Labelled Tetramer	HPV18.E6	KLPDCTL	HLA-A*0201	13-21	UA089005
HPV	HLA-A*0201/KLTNT-GLYQL-PE Labelled Tetramer	HPV18.E6	KLTNTGLYNL	HLA-A*0201	92-101	UA089006
HPV	HLA-A*0201/TLODIVIHL-PE Labelled Tetramer	HPV18.E7	TLODIVIHL	HLA-A*0201	7~15	UA089007
HPV	HLA-A*0201/QFLNTL-FV-PE Labelled Tetramer	HPV18.E7	QFLNTLFSV	HLA-A*0201	88-97	UA089008
HPV	HLA-A*1101/GVNHQLPAR-PE Labelled Tetramer	HPV18.E7	GVNHQLPAR	HLA-A*1101	43-52	UA089009
Influenza A Virus	H-2D(b)/ASNENMETM-PE Labelled Tetramer	Flu.NP	ASNENMETM	H-2Db	366-374	UA089010
Influenza A Virus	H-2K(d)/TYQR-TRALY-PE Labelled Tetramer	Flu.NP	TYQRTRALY	H-2Kd	147-155	UA089011
Influenza A Virus	H-2D(b)/ASNEN-MDTM-PE Labelled Tetramer	Flu.NP	ASNENMDTM	H-2Db	366-374	UA089012
LCMV	H-2D(b)/KAVYNFATM-PE Labelled Tetramer	GP 33	KAVYNFATM	H-2Db	33-41	UA089013
LCMV	H-2D(b)/FQPGQGFVK-PE Labelled Tetramer	LCMV NP	FQPGQGFVK	H-2Db	396-404	UA089014
Tumor-related	HLA-A*1101/VVGADGVK-PE Labelled Tetramer	KRAS	VVGADGVK	HLA-A*1101	7~16	UA089015
Tumor-related	HLA-A*1101/VVGAGVGK-PE Labelled Tetramer	KRAS	VVGAGVGK	HLA-A*1101	7~16	UA089016
Tumor-related	HLA-A*0201/KLVVGAGV-PE Labelled Tetramer	KRAS	KLVVGAGV	HLA-A*0201	5~14	UA089017
Tumor-related	HLA-A*0201/SLLMWITQC-PE Labelled Tetramer	NY-ESO1	SLLMWITQC	HLA-A*0201	157-165	UA089018
Melanoma	HLA-A*0201/LMWITQCFL-PE Labelled Tetramer	NY-ESO2	LMWITQCFL	HLA-A*0201	159-167	UA089019
Melanoma	H-2Db(b)/MMFPNA-P1-PE Labelled Tetramer	WT1	RMFPNAPL	H-2Db	126-134	UA089020
Melanoma	HLA-A*0201/CMTWV-PE Labelled Tetramer	WT2	CMTWVNMDM	HLA-A*0201	235-243	UA089021
Melanoma	HLA-A*1101/KTCQRKSF-PE Labelled Tetramer	WT3	KTCQRKSF	HLA-A*1101	386-394	UA089022
Ovarian Cancer	H-2K(b)/SINFEKL-PE Labelled Tetramer	OVA	SINFEKL	H-2Kb	257-264	UA089023

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next